CCT007093
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406516

CAS#: 176957-55-4

Description: CCT007093 is a potent PPM1D inhibitor or WIP1 inhibitor that selectively reduces viability of human tumour cell lines. CCT007093 enhances liver regeneration and increases the survival rate of mice after major hepatectomy. CT007093 treatment appeares to promote apoptosis in breast cancer cells and skin transformed keratinocytes that ectopically expressed Wip1, demonstrating that the effect of CCT007093 differs based on the level of Wip1 expression. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.


Chemical Structure

img
CCT007093
CAS# 176957-55-4

Theoretical Analysis

MedKoo Cat#: 406516
Name: CCT007093
CAS#: 176957-55-4
Chemical Formula: C15H12OS2
Exact Mass: 272.03296
Molecular Weight: 272.39
Elemental Analysis: C, 66.14; H, 4.44; O, 5.87; S, 23.54

Price and Availability

Size Price Availability Quantity
100.0mg USD 450.0 2 Weeks
200.0mg USD 750.0 2 Weeks
500.0mg USD 1250.0 2 Weeks
1.0g USD 2150.0 2 Weeks
2.0g USD 3150.0 2 Weeks
5.0g USD 4650.0 2 Weeks
Bulk inquiry

Synonym: CCT007093; CCT-007093; CCT 007093.

IUPAC/Chemical Name: (2E,5E)-2,5-Bis(2-thienylmethylene)-cyclopentanone.

InChi Key: KPFZCKDPBMGECB-WGDLNXRISA-N

InChi Code: InChI=1S/C15H12OS2/c16-15-11(9-13-3-1-7-17-13)5-6-12(15)10-14-4-2-8-18-14/h1-4,7-10H,5-6H2/b11-9+,12-10+

SMILES Code: O=C1/C(CC/C1=C\C2=CC=CS2)=C/C3=CC=CS3

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 272.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lee JS, Park JR, Kwon OS, Kim H, Fornace AJ Jr, Cha HJ. Off-target response of a Wip1 chemical inhibitor in skin keratinocytes. J Dermatol Sci. 2014 Feb;73(2):125-34. doi: 10.1016/j.jdermsci.2013.09.003. Epub 2013 Sep 13. PubMed PMID: 24126074.

2: Pivovarov AS, Murzina GB, Tret'iakova MS, Makhnovskiĭ DA. [Role of serine/threonine and tyrosine protein phosphatases in command Helix lucorum neurons at the cellular correlate of habituation]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2013 Mar-Apr;63(2):256-68. Russian. PubMed PMID: 23866612.

3: Buss MC, Read TA, Schniederjan MJ, Gandhi K, Castellino RC. HDM2 promotes WIP1-mediated medulloblastoma growth. Neuro Oncol. 2012 Apr;14(4):440-58. doi: 10.1093/neuonc/nos001. Epub 2012 Feb 29. PubMed PMID: 22379189; PubMed Central PMCID: PMC3309853.

4: Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res. 2010;12(3):R41. doi: 10.1186/bcr2595. Epub 2010 Jun 24. PubMed PMID: 20576088; PubMed Central PMCID: PMC2917036.

5: Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 2009 Apr 1;15(7):2269-80. doi: 10.1158/1078-0432.CCR-08-2403. Epub 2009 Mar 17. PubMed PMID: 19293255.

CCT007093

100.0mg / USD 450.0


Additional Information